FOR IMMEDIATE RELEASE
ANNAPOLIS, MD — In a poignant and urgent dispatch from the front lines of cancer advocacy, Dr. Kelly Shanahan, President of METAvivor Research and Support, has officially launched the organization’s 2026 grant cycle. Amidst a personal schedule defined by grueling travel for clinical trials and international advocacy, Dr. Shanahan revealed that the organization has received a record-breaking number of Letters of Intent (LoIs) from the scientific community, signaling a critical juncture in the quest to transition metastatic breast cancer (MBC) from a terminal diagnosis to a manageable chronic condition.
With a strategic fundraising target set at $3.75 million for the current fiscal year, the organization is pivoting toward a "realistic yet ambitious" financial model. This comes at a time when the demand for high-level translational research has never been higher, with three-quarters of all applicants vying for the prestigious $450,000 translational award mechanism.
Main Facts: A Surge in Scientific Interest and Financial Necessity
The 2026 grant cycle represents a milestone for METAvivor, an organization unique in its commitment to dedicating 100% of all donations to metastatic research. The primary facts surrounding this announcement underscore both the progress of the scientific community and the immense pressure on non-profit funding structures.
Record-Breaking Engagement
For the upcoming cycle, METAvivor has seen its highest volume of Letters of Intent to date. This influx suggests that despite a volatile global economy, the pipeline for metastatic breast cancer research is expanding. Scientists are increasingly looking toward specialized organizations to fund high-risk, high-reward projects that larger, more generalized federal agencies may overlook.
The Dominance of Translational Research
Of the record number of LoIs received, approximately 75% are focused on the $450,000 translational award. Translational research is often described as the "bench-to-bedside" process, where laboratory discoveries are fast-tracked into clinical applications. The high demand for this specific award highlights a shift in the scientific community’s focus: the goal is no longer just understanding the biology of the disease, but actively developing treatments that can be implemented in a clinical setting within a shorter timeframe.
The $3.75 Million Mandate
To meet the needs of these researchers, Dr. Shanahan has set a fundraising goal of $3.75 million. While the organization has historically aimed for even loftier targets, the current economic climate—marked by inflation and shifting philanthropic priorities—has necessitated a more grounded approach. However, this "realistic" goal remains a significant undertaking that relies heavily on grassroots support and micro-donations.
Chronology: The Road to the 2026 Grant Awards
The process of awarding millions of dollars in research grants is a multi-year endeavor that requires meticulous planning, rigorous peer review, and sustained advocacy.
Phase I: The Call for Letters of Intent (Current Phase)
The cycle began with the solicitation of LoIs. These brief documents allow the organization’s scientific advisory board to vet the potential impact of a study before inviting a full, detailed proposal. The record numbers reported by Dr. Shanahan indicate that the 2026 cycle will be the most competitive in the organization’s history.
Phase II: The Review Process (Winter 2024 – Spring 2025)
Once the LoIs are screened, selected researchers will be invited to submit full proposals. This leads into the dual-review process that defines METAvivor’s methodology. Every proposal undergoes a two-tiered evaluation:
- Scientific Review: Conducted by experts in oncology and molecular biology to ensure technical merit.
- Patient Advocate Review: Conducted by individuals living with metastatic breast cancer to ensure the research aligns with the actual needs and priorities of the patient community.
Phase III: The Funding Announcement and Disbursement (Late 2025)
Following the review, the board will finalize the list of awardees. The funds raised during the 2024-2025 fiscal year will be earmarked for these 2026 grants, ensuring that the money is ready for disbursement as soon as the contracts are signed.
Phase IV: Clinical Application
For translational awards, the timeline extends into the future as researchers move their findings into Phase I and Phase II clinical trials, the very trials that patients like Dr. Shanahan participate in to sustain their lives.
Supporting Data: The Economics of Metastatic Research
To understand the weight of Dr. Shanahan’s announcement, one must look at the disparity in breast cancer funding. Historically, only 2% to 5% of all breast cancer research funding is dedicated to the metastatic stage—the stage responsible for nearly all breast cancer deaths.
The Cost of Innovation
The $450,000 translational award is designed to bridge the "Valley of Death" in drug development—the gap between initial discovery and the start of human trials.
- Personnel Costs: A typical high-level research team requires significant funding for post-doctoral fellows and lab technicians.
- Equipment and Reagents: Advanced genomic sequencing and CRISPR technology can cost thousands of dollars per run.
- Regulatory Compliance: Moving toward a clinical trial involves expensive FDA-mandated safety testing.
The Power of Micro-Donations
Dr. Shanahan’s call to "give up a fancy coffee" is more than a rhetorical device; it is a mathematical strategy.
- If 750,000 individuals donated the cost of a $5 coffee, the $3.75 million goal would be met instantly.
- Small-scale recurring donations provide a predictable revenue stream that allows the organization to commit to multi-year grants without the volatility of major corporate shifts.
Official Responses: A Leader’s Perspective
Dr. Kelly Shanahan’s letter serves as the official statement of the organization, but its tone is notably different from typical corporate communications. As a physician living with metastatic breast cancer, her "Official Response" is rooted in the lived experience of the patient.
"I feel like all I do is unpack my suitcase, do laundry, and then put the clothes back in the suitcase," Dr. Shanahan noted, highlighting the relentless pace required to keep the organization moving forward while simultaneously battling the disease.
Her leadership emphasizes two critical pillars:
- Scientific Rigor: The insistence on both scientific and patient reviewers ensures that the $3.75 million is spent on research that is both intellectually sound and practically relevant.
- Urgency: The "realistic" goal of $3.75 million is a direct response to the "uncertainty in the world." Shanahan acknowledges that while the need is infinite, the resources must be managed with precision to ensure that every dollar awarded has the maximum possible impact on patient longevity.
The organization’s stance is clear: they cannot award a single dollar without the support of the public. This transparency serves to empower the donor, making them an active participant in the scientific process.
Implications: What is at Stake for the MBC Community?
The implications of the 2026 grant cycle and the current fundraising drive extend far beyond the walls of a laboratory. They represent the difference between life and death for the hundreds of thousands of people living with Stage IV breast cancer.
The Future of Patient-Led Research
METAvivor’s model, which includes patient advocates in the grant review process, is setting a new standard for medical research. The implication is that research is becoming more "democratized." Patients are no longer just the subjects of study; they are the architects of the research agenda. This ensures that quality of life and long-term survival are prioritized over incremental scientific curiosity.
The Threat of Underfunding
If the $3.75 million goal is not met, the "record number" of LoIs will result in a record number of rejections for potentially life-saving research. The $450,000 translational awards are often the only lifeline for mid-sized labs that are too large for small seed grants but too focused on metastasis for large-scale government funding. A shortfall in fundraising directly translates to a slowdown in the development of new drug therapies.
The Psychological Impact on the Community
Dr. Shanahan’s travel—1,100 miles each way for a clinical trial—is a stark reminder of the "treatment burden" faced by patients. The success of this grant cycle offers hope that future treatments might be more accessible, less toxic, and more effective. For the MBC community, these grants are a signal that they have not been forgotten in the broader "pink ribbon" narrative that often focuses on early-stage detection and "cures" that do not apply to those already metastatic.
Conclusion: A Call to Action
As Dr. Shanahan continues her journey through airports and clinical trials, the 2026 grant cycle moves forward. The organization’s message is a blend of scientific optimism and economic realism. The record-breaking interest from the scientific community proves that the answers to metastatic breast cancer are within reach; the only remaining variable is the capital required to grasp them.
The $3.75 million goal is not just a number on a balance sheet—it is a collective investment in time for those who have very little of it left. As the 2026 cycle progresses, the eyes of the oncology world will be on METAvivor to see if a grassroots movement can indeed fund the next great breakthrough in cancer science.
About METAvivor:
METAvivor Research and Support is a 501(c)(3) non-profit organization dedicated to the specific fight against metastatic breast cancer. It is the only organization in the US that exclusively funds MBC research and uses 100% of all donations for that purpose. For more information or to contribute to the 2026 grant cycle, visit [METAvivor.org].
About the Author
